Navigation Links
Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
Date:6/24/2008

KENILWORTH, N.J., June 24 /PRNewswire-FirstCall/ -- The Board of Directors of Schering-Plough Corporation (NYSE: SGP) today declared a quarterly dividend of 6.5 cents per common share. Payment will be made on Aug. 26, 2008, to shareholders of record at the close of business on Aug. 1, 2008. As of March 31, 2008, there were 1,621,414,244 common shares outstanding.

The Board of Directors today also declared a quarterly dividend of $3.75 per share on the 2007 Mandatory Convertible Preferred Stock. Payment will be made on Aug. 15, 2008, to holders of record at the close of business on Aug. 1, 2008. As of March 31, 2008, there were 10,000,000 shares of 2007 Mandatory Convertible Preferred Stock outstanding.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Schering-Plough Schedules Conference Call and Webcast for 2008 Second Quarter Earnings
2. Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations
3. Schering-Plough Schedules Webcast for Annual Meeting of Shareholders
4. Intervet/Schering-Plough Animal Health Outlines Strength of the Combination
5. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
6. Schering-Plough CEO Buys $2 Million in Common Shares
7. Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe
8. Schering-Plough Reports Financial Results for First Quarter of 2008
9. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
10. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
11. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... San Diego, CA (PRWEB) December 23, 2014 ... Contest where their Twitter followers can submit their ... for themselves and their lab mates. , For those ... beloved lab mates, the Pipette.com Holiday in the Lab ... encourages Pipette.com Twitter followers to send pictures ...
(Date:12/24/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ) ... Application (CTA) with the United Kingdom,s ... approval to initiate clinical trials for the continued development ... on the Company receiving CTA regulatory approval, the Company ... the safety, tolerability and dose escalation of Anatabine Citrate ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy & ... it has signed a letter of intent to ... developed and patented a nanotechnology-based development platform used ... that enable rapid on-site collection and testing to ... health issues in an immediate, non-invasive and cost-effective ...
(Date:12/22/2014)... Fertility Associates of Memphis has announced ... , a network of more than 20 contributing ... have fast access to a national pool of frozen ... Fertility Associates of Memphis is the only fertility clinic ... , Dr. William Kutteh , director of Fertility ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3
... , , CAMBRIDGE, ... ), a biopharmaceutical company engaged in the discovery and development of ... pricing of an underwritten offering of 7,248,936 shares of its common ... and commissions and estimated offering expenses, the company expects to receive ...
... , , SAN DIEGO, Aug. 5 ... will provide partial funds for long-term follow-up testing of patients enrolled ... The funding will enable Ceregene to collect and analyze more ... Parkinson,s disease who were enrolled in the double-blind, controlled trial which ...
... Mass., Aug. 5 NxStage Medical, Inc. (Nasdaq: NXTM ... revenue for the second quarter of 2009 of $36.4 million, an ... for the second quarter of 2008. , , ... in Home, solid machine sales in Critical Care, and continued progress ...
Cached Biology Technology:Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock 2Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients 2Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients 3Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients 4NxStage Reports Second Quarter 2009 Financial Results 2NxStage Reports Second Quarter 2009 Financial Results 3NxStage Reports Second Quarter 2009 Financial Results 4NxStage Reports Second Quarter 2009 Financial Results 5NxStage Reports Second Quarter 2009 Financial Results 6NxStage Reports Second Quarter 2009 Financial Results 7NxStage Reports Second Quarter 2009 Financial Results 8NxStage Reports Second Quarter 2009 Financial Results 9NxStage Reports Second Quarter 2009 Financial Results 10NxStage Reports Second Quarter 2009 Financial Results 11NxStage Reports Second Quarter 2009 Financial Results 12
(Date:12/3/2014)... 2014 As part of our commitment to ... pleased to announce the release of a new reader ... the workforce data that they need. The ... by existing readers. Many such devices have serious shortcomings ... technology. Older models force users to navigate numerous complicated ...
(Date:11/21/2014)... YORK , Nov. 19, 2014  Earlier this ... at New York College, and one of the most ... biosensor signals that are transmitted from Smartphones to third ... were Smartphones and has one of the earliest known ... discussing its usage in the military, child care, elder ...
(Date:11/21/2014)... -- C-Labs LLC, a leading provider of remote and ... announced the appointment of John Traynor to ... advisor to the firm, Mr. Traynor will now oversee ... out of the C-Labs office in Redmond, ... , Chief Executive Officer. Photo - ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... pleased to announce the 2010 Yeast Genetics and Molecular ... of British Columbia (UBC) in Vancouver, Canada. This ... eukaryotic biology in yeast. Program highlights include presentations ... is also a Member of Parliament. The ...
... discovered a key reason why a form of leukemia ... phase called blast crisis. The study, led by cancer ... G. James Cancer Hospital and Richard J. Solove Research ... when immature white blood cells lose a molecule called ...
... Diego, paleoceanographer Richard Norris is one of 41 scientists presenting ... and myriad other organisms 30 years after the theory was ... paper being released Friday in the journal Science ... the cause of the mass extinction. Norris, contribution to the ...
Cached Biology News:2010 Yeast Genetics and Molecular Biology Meeting 22010 Yeast Genetics and Molecular Biology Meeting 3Study identifies key cause of chronic leukemia progression 230 years later, what killed the dinosaurs is revisited 230 years later, what killed the dinosaurs is revisited 3
ImageQuant 100 UV, 1 EA. Category: ImageQuant CCD Imagers....
ImageQuant 300, 1 EA. Category: ImageQuant CCD Imagers....
Recombinant Feline IL-12/IL-23 p40...
RABBIT ANTI ISOCITRATE DEHYDROGENASE...
Biology Products: